Table 3.
Variable | Non-DM | DM | P-value |
---|---|---|---|
(N=128) | (N=64) | ||
Age at Exam (years) | 62.6 ± 9.2 | 62.7± 9.2 | .94 |
Gender, n (%) | 48 (38%) | 24 (38%) | -- |
BMI of Patient | 28.8± 4.9 | 30.4± 5.9 | .04 |
BMI>30, n (%) | 48 (38%) | 29 (45%) | .30 |
Waist>102M, 88F, n(%) | 50 (39%) | 31 (48%) | .21 |
Metabolic Syndrome, n (%) | 29 (23%) | 35 (56%) | <.001 |
Verified Hypertension, n(%) | 54 (42%) | 29 (45%) | .68 |
CAD (%) | 33 (26%) | 21 (33%) | .31 |
HF (n%) | 0 (0%) | 0 (0%) | -- |
MI n,(%) | 10 (8%) | 10 (16%) | .09 |
Atrial Fib/Flutter n,(%) | 4 (3%) | 5 (8%) | .15 |
Stroke n,(%) | 0 (0%) | 0 (0%) | -- |
Beta Blocker, n(%) | 26 (22%) | 19 (31%) | .17 |
Calcium Channel Blocker, n(%) | 17 (14%) | 5 (8%) | .24 |
ACE Inhibitor, n(%) | 10 (8%) | 17 (28%) | <.001 |
Antilipemic Therapy, n(%) | 27 (23%) | 25 (41%) | .01 |
Total Cholesterol (mg/dL) | 201.7 ± 38.1 | 188.9 ± 40.8 | .04 |
LDL Cholesterol (mg/dL) | 126.8 ± 33.3 | 114.9 ± 34.2 | .02 |
Triglycerides (mg/dL) | 153.5 ± 87.9 | 180.4 ± 117.3 | .08 |
HDL (mg/dL) <40M, <50F, n(%) | 64 (51%) | 46 (73%) | .004 |
NT-proBNP (pg/mL), median (Q1, Q3) | 76.9 (32.3, 153.6) | 61.7 (15.6, 126) | 0.85 |
Aldosterone (pg/ml), median (Q1, Q3) | 4.8 (2.9, 9.2) | 5.1 (2.5, 8.3) | 0.64 |
Insulin (uU/mL), median (Q1, Q3) | 5.6 (3.6, 8.1) | 8.3 (5, 15) | <.001 |
Creatinine (mg/dL), median (Q1, Q3) | 0.9 (0.8, 1) | 0.9 (0.7, 1) | .63 |
SBP (mmHg) | 131.7 ± 19 | 134 ± 17 | .43 |
DBP (mmHg) | 73.6 ± 10.2 | 72.8 ± 7.3 | .59 |
Serum Glucose (mg/dL), median (Q1, Q3) | 94 (89, 100) | 129 (111, 158) | <.001 |
ACE angiotensin-converting enzyme, BMI body mass index, CAD coronary artery disease, HF heart failure, DBP diastolic blood pressure, MI myocardial infarction, HDL high-density lipoprotein, LDL low-density lipoprotein, NT-proBNP n-terminal pro hormone b-type natriuretic peptide, SBP systolic blood pressure
dL deciliter, mg milligram, mmHg millimeters of mercury, Pg picogram, uU international unit